KRKA Generics Company Intelligence Report

Espicom Healthcare Intelligence

- Pub ID: ESPI2286622

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Additional Information

Krka was established in Slovenia in 1954, and has grown to become one of the largest generic drug manufacturers in Central and Eastern Europe. With the acquisition of Lek by Novartis in late 2002, Krka is now the only major Slovenian-owned pharmaceutical company.

Krka’s largest therapeutic category is cardiovascular drugs, followed by alimentary tract and metabolism, CNS and anti-infectives.

Krka Group reported sales worth 949.9 million euros (US$1,397.7 million) in 2008, an increase of 21.6% over 2007. Net profit stood at 155.9 million euros (US$229.4 million), an increase of 17.3% over 2007.

Exports accounted for 89.1% of sales in 2008. Central Europe was the firm’s largest region in terms of sales, accounting for 26.7% of overall sales, followed by Eastern Europe with 24.4% and Western Europe and Overseas with 23.6%. The domestic Slovenian market accounted for 11.0% of sales, making this the smallest of Krka’s regions in terms of sales.

In 2007, Krka acquired the German firm, TAD Pharma. This represented the firm’s first takeover, giving the firm direct entry onto the German pharmaceutical market.

In June 2008, Krka became a minority owner of two Chinese pharmaceutical and chemical companies, gaining a 7.5% ownership share of both.

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: Monday - Thursday: 3:00am - 7:00pm eastern time

Fridays: 3:00am - 6:00pm eastern time